
1. antiviral res. 2013 nov;100(2):297-9. doi: 10.1016/j.antiviral.2013.08.024. epub 
2013 sep 8.

baseline sensitivity hsv-1 hsv-2 clinical isolates defined
acyclovir-resistant strains helicase-primase inhibitor pritelivir.

field hj(1), huang ml, lay em, mickleburgh i, zimmermann h, birkmann a.

author information: 
(1)department veterinary medicine, university cambridge, madingley road,
cambridge cb3 0es, united kingdom. electronic address: hjf10@cam.ac.uk.

fifty-nine us isolates hsv-1 hsv-2 obtained 1998 2004 were
tested sensitivity helicase-primase inhibitor, pritelivir (aic316, bay
57-1293) plaque-reduction assay. isolates, collected prior to
any clinical use primase-helicase inhibitors, sensitive showed mean
ec50 values 0.026 0.029μm hsv-1 hsv-2, respectively. furthermore, 
several laboratory-selected acyclovir-resistant hsv mutants also sensitive
to pritelivir. data provide baseline hsv sensitivity pritelivir in
general population introduced broadly used treat hsv
infection. data also validate pritelivir appropriate therapy for
nucleoside-resistant hsv infections.

copyright © 2013 elsevier b.v. rights reserved.

doi: 10.1016/j.antiviral.2013.08.024 
pmid: 24021190  [indexed medline]

